Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more

Add To Watchlist

Recent & Breaking News (NDAQ:CLDX)

Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer

GlobeNewswire July 1, 2015

Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of RINTEGA(R) (rindopepimut) in Newly Diagnosed Glioblastoma

GlobeNewswire June 29, 2015

Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met

GlobeNewswire May 31, 2015

Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma

GlobeNewswire May 28, 2015

Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference

GlobeNewswire May 27, 2015

Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting

GlobeNewswire May 13, 2015

Celldex Reports First Quarter 2015 Results

GlobeNewswire April 29, 2015

Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology

GlobeNewswire April 6, 2015

Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma

GlobeNewswire April 6, 2015

Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A

GlobeNewswire March 17, 2015

Celldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health Care Conference

GlobeNewswire March 3, 2015

Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 27, 2015

Celldex Therapeutics Prices Public Offering of Common Stock

GlobeNewswire February 25, 2015

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire February 24, 2015

Celldex Reports Fourth Quarter and Year-End 2014 Results

GlobeNewswire February 24, 2015

Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma

GlobeNewswire February 23, 2015

Celldex to Report Fourth Quarter and Fiscal 2014 Business/Financial Results and Host 2015 Corporate Strategy Conference Call

GlobeNewswire February 19, 2015

Celldex Therapeutics Announces Upcoming Presentation at the 2015 Leerink Global Healthcare Conference

GlobeNewswire February 9, 2015

Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors

GlobeNewswire January 29, 2015

Celldex Therapeutics Announces Appointment to Board of Directors

GlobeNewswire December 18, 2014